Temozolomide is the most common and effective chemotherapy drug for malignant glioma patients, but the efficacy of alkylating agents such as TMZ is related to the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter in gliomas. This evidence concerns the gene MGMT and central nervous system cancer.